Generate:Biomedicines reviews

Greed and impatience have made the exec leaders dismiss opportunities to stand out and differentiate and talented individuals and teams are undervalued. Many execs have no biotech experience, are focused on themselves getting rich quick and have lost interest in being engaged leaders and holding themselves and other leaders accountable. Clinging on to the AI hype while they still can, but lacking vision to realize the company’s early promise. The culture has tanked and people are disillusioned. Bad behavior is rewarded and nothing changes to improve culture despite lip service. The pay is good but not worth the burn out and bad culture.

1. A portion of the research team appears to be coasting and work on "fake" scopes 2. The research infrastructure is made intentionally complicated to drive so called "impact" over efficiency 4. Research direction frequently shifts, slowing progress 5. Leadership lacks focus and consistent vision in AI + Bio. 6. Increasing bureaucracy from big-company hires (VP, director level) who are career-ladder climbers and prioritize politics over progress 7. Complex dynamics make execution and collaboration confusing.